Medicine

Integrating liver endpoints in professional trials of cardiovascular as well as kidney disease

.Nature Medicine, Released online: 03 September 2024 doi:10.1038/ s41591-024-03223-zThis Standpoint calls for incorporation of individuals with MASLD as well as size of liver end results in cardio-- kidney-- metabolic tests, when information propose mechanistically tenable perks and medical security-- and summarizes factors to consider for test style and regulatory approval.